DE60117978D1 - Modifizierung des hepatitis b kernantigens - Google Patents

Modifizierung des hepatitis b kernantigens

Info

Publication number
DE60117978D1
DE60117978D1 DE60117978T DE60117978T DE60117978D1 DE 60117978 D1 DE60117978 D1 DE 60117978D1 DE 60117978 T DE60117978 T DE 60117978T DE 60117978 T DE60117978 T DE 60117978T DE 60117978 D1 DE60117978 D1 DE 60117978D1
Authority
DE
Germany
Prior art keywords
hepatitis
hbcag
protein
nuclear
modifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60117978T
Other languages
English (en)
Other versions
DE60117978T2 (de
Inventor
Mark Page
Jing-Li Li
Paul Pumpens
Galina Borisova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma Ltd
Original Assignee
UCB Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0015308A external-priority patent/GB0015308D0/en
Priority claimed from GB0024544A external-priority patent/GB0024544D0/en
Application filed by UCB Pharma Ltd filed Critical UCB Pharma Ltd
Application granted granted Critical
Publication of DE60117978D1 publication Critical patent/DE60117978D1/de
Publication of DE60117978T2 publication Critical patent/DE60117978T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE60117978T 2000-06-22 2001-06-22 Modifizierung des hepatitis b kernantigens Expired - Lifetime DE60117978T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0015308A GB0015308D0 (en) 2000-06-22 2000-06-22 Modification of hepatitis B core antigen
GB0015308 2000-06-22
GB0024544 2000-10-06
GB0024544A GB0024544D0 (en) 2000-10-06 2000-10-06 Modification of hepatitus B core antigen
PCT/GB2001/002817 WO2001098333A2 (en) 2000-06-22 2001-06-22 Modification of hepatitis b core antigen

Publications (2)

Publication Number Publication Date
DE60117978D1 true DE60117978D1 (de) 2006-05-11
DE60117978T2 DE60117978T2 (de) 2006-11-02

Family

ID=26244528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117978T Expired - Lifetime DE60117978T2 (de) 2000-06-22 2001-06-22 Modifizierung des hepatitis b kernantigens

Country Status (11)

Country Link
US (1) US20040054139A1 (de)
EP (1) EP1294893B1 (de)
JP (1) JP2004500868A (de)
AT (1) ATE320493T1 (de)
AU (2) AU2001266163B2 (de)
CA (1) CA2413546C (de)
DE (1) DE60117978T2 (de)
DK (1) DK1294893T3 (de)
ES (1) ES2260235T3 (de)
PT (1) PT1294893E (de)
WO (1) WO2001098333A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7546500A (en) * 1999-10-08 2001-04-23 Celltech Pharma Europe Limited Designing immunogens
CN100360556C (zh) * 2000-04-07 2008-01-09 利兹创新有限公司大学 乙型肝炎核心抗原的融合蛋白
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20040146524A1 (en) * 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
WO2003072731A2 (en) * 2002-02-21 2003-09-04 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
BR0312792A (pt) 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
AU2004224762B2 (en) 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7320795B2 (en) 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7144712B2 (en) 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
WO2005011571A2 (en) * 2003-07-30 2005-02-10 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US20050175583A1 (en) * 2003-12-02 2005-08-11 Lawrence Tamarkin Methods and compositions for the production of monoclonal antibodies
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
PE20142330A1 (es) 2008-12-09 2015-01-14 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
RU2518291C2 (ru) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
JP2013503623A (ja) 2009-09-03 2013-02-04 ファイザー バクシーンズ エルエルシー Ｐｃｓｋ９ワクチン
EP2942061A3 (de) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
US9446120B2 (en) 2011-04-15 2016-09-20 Osaka University DNA vaccine
EP2891497B1 (de) * 2012-08-31 2020-07-01 Osaka University Dna-impfstoffhaltiges vegf-spezifisches epitop und/oder angiopoietin-2-spezifisches epitop
JP6001974B2 (ja) 2012-09-21 2016-10-05 アンジェスＭｇ株式会社 アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
CN104341506A (zh) * 2013-07-30 2015-02-11 复旦大学 一种重组融合蛋白及其用途
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
WO2015133467A1 (ja) * 2014-03-06 2015-09-11 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
EP3762010A4 (de) 2018-03-06 2022-04-06 Precigen, Inc. Hepatitis-b-impfstoffe und verwendungen davon
AU2020342385A1 (en) * 2019-08-29 2022-03-31 Triad National Security, Llc Hepatitis B virus vaccines
EP4037708A1 (de) 2019-09-30 2022-08-10 Gilead Sciences, Inc. Hbv-impfstoffe und verfahren zum behandeln von hbv

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
AU775939B2 (en) * 1998-11-05 2004-08-19 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization

Also Published As

Publication number Publication date
AU6616301A (en) 2002-01-02
WO2001098333A3 (en) 2002-03-28
EP1294893B1 (de) 2006-03-15
AU2001266163B2 (en) 2006-07-13
DK1294893T3 (da) 2006-07-03
WO2001098333A2 (en) 2001-12-27
DE60117978T2 (de) 2006-11-02
ES2260235T3 (es) 2006-11-01
US20040054139A1 (en) 2004-03-18
JP2004500868A (ja) 2004-01-15
EP1294893A2 (de) 2003-03-26
CA2413546A1 (en) 2001-12-27
CA2413546C (en) 2011-06-14
ATE320493T1 (de) 2006-04-15
PT1294893E (pt) 2006-08-31

Similar Documents

Publication Publication Date Title
DE60117978D1 (de) Modifizierung des hepatitis b kernantigens
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
ATE323758T1 (de) Attenuierte lebendimpfstoffe
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
EA200201077A1 (ru) Коровые антигенные химерные белки гепатита в
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
DK1283887T3 (da) Kimære Arterivirus-lignende partikler
WO2002013855A3 (en) Vaccines containing ribavirin and methods of use thereof
DK1035133T3 (da) Fusionsproteiner, der omfatter bærere, som kan inducere et dobbelt immunrespons
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
EP1274851A4 (de) Für eine prozessierungskomponente aus der n-terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
FI923020A (fi) Inte a inte b-sekvenser.
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
SE0002498D0 (sv) Papillomavirus vaccine
DE60142836D1 (de) Nicht menschliche tiermodelle die toleranz gegenüber hepatitis c virus immunogene aufweisen
DK1237571T3 (da) Toscana-virus-nukleinprotein
TH58564B (th) อนุภาคไวรัสที่มีอีพิโทปด้านในจากแหล่งภายนอก
AU4394101A (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition